{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:32:53Z","timestamp":1791113573153,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2005,7]]},"DOI":"10.1053\/j.ajkd.2005.03.005","type":"journal-article","created":{"date-parts":[[2005,12,13]],"date-time":"2005-12-13T09:08:52Z","timestamp":1134464932000},"page":"94-101","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":80,"title":["Effect of Spironolactone on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Oligo-Anuric Hemodialysis Patients"],"prefix":"10.1053","volume":"46","author":[{"given":"Evan","family":"Gross","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Rothstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dombek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrikas Irmantas","family":"Juknis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1053\/j.ajkd.2005.03.005_bib1","first-page":"S17","article-title":"USRDS 2001 Annual Data Report","volume":"38","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.03.005_bib2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/0272-6386(95)90492-1","article-title":"Hypertension in hemodialysis population","volume":"26","author":"Salem","year":"1995","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ajkd.2005.03.005_bib3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/ki.1995.22","article-title":"Clinical and echocardiographic disease in patients starting end-stage renal disease therapy","volume":"47","author":"Foley","year":"1995","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.03.005_bib4","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.1989.192","article-title":"Impact of left ventricular hypertrophy on survival in end-stage renal disease","volume":"36","author":"Silberberg","year":"1989","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.03.005_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1291\/hypres.22.17","article-title":"Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension","volume":"22","author":"Sato","year":"1999","journal-title":"Hypertens Res"},{"key":"10.1053\/j.ajkd.2005.03.005_bib6","first-page":"13","article-title":"Effect of selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone induced hypertension and cardiac fibrosis","author":"Frierdich","year":"1998","journal-title":"American Society of Hypertension 13th Scientific Meeting"},{"key":"10.1053\/j.ajkd.2005.03.005_bib7","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/S0895-7061(99)00066-7","article-title":"Involvement of aldosterone in left ventricular hypertrophy of patients with end-stage renal failure treated with hemodialysis","volume":"12","author":"Sato","year":"1999","journal-title":"Am J Hypertens"},{"key":"10.1053\/j.ajkd.2005.03.005_bib8","first-page":"399","article-title":"Central infusion of aldosterone increases blood pressure by mechanisms independent of Na retention","volume":"12","author":"Peysner","year":"1990","journal-title":"Clin Exp Hypertens A"},{"key":"10.1053\/j.ajkd.2005.03.005_bib9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1046\/j.1523-1755.2000.00971.x","article-title":"Brain mineralocorticoid receptors and centrally regulated functions","volume":"57","author":"De Kloet","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.03.005_bib10","first-page":"3339","article-title":"The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans","volume":"83","author":"Young","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2005.03.005_bib11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000054384","article-title":"Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans","volume":"68","author":"Deuschle","year":"1998","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.ajkd.2005.03.005_bib12","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1046\/j.1523-1755.2000.00974.x","article-title":"11Beta-hydroxysteroid dehydrogenase in human vascular cells","volume":"57","author":"Hatakeyama","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.03.005_bib13","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0039-128X(94)00026-9","article-title":"Aldosterone biosynthesis and action in vascular cells","volume":"60","author":"Takeda","year":"1995","journal-title":"Steroids"},{"key":"10.1053\/j.ajkd.2005.03.005_bib14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1161\/01.CIR.92.2.175","article-title":"Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart","volume":"92","author":"Lombes","year":"1995","journal-title":"Circulation"},{"key":"10.1053\/j.ajkd.2005.03.005_bib15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hene","year":"1982","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.03.005_bib16","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1177\/039139888300600508","article-title":"Catecholamines, renin, aldosterone and arterial pressure in patients on chronic hemodialysis treatment","volume":"6","author":"Ratge","year":"1983","journal-title":"Int J Artif Organs"},{"key":"10.1053\/j.ajkd.2005.03.005_bib17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/j.1523-1755.2004.00931.x","article-title":"Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients","volume":"66","author":"Michea","year":"2004","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.03.005_bib18","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1093\/ndt\/gfg388","article-title":"Safety of low-dose spironolactone administration in chronic hemodialysis patients","volume":"18","author":"Saudan","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2005.03.005_bib19","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1093\/ndt\/gfg413","article-title":"Is spironolactone safe for dialysis patients?","volume":"18","author":"Hussain","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2005.03.005_bib20","doi-asserted-by":"crossref","first-page":"40A","DOI":"10.1016\/0002-9149(93)90244-7","article-title":"Dose-related cardiovascular effects of spironolactone","volume":"71","author":"Schohn","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1053\/j.ajkd.2005.03.005_bib21","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1210\/endo-118-2-819","article-title":"Intracerebral infusion of aldosterone induces hypertension in rats","volume":"118","author":"Gomez-Sanchez","year":"1986","journal-title":"Endocrinology"},{"key":"10.1053\/j.ajkd.2005.03.005_bib22","first-page":"E482","article-title":"Intracerebroventricular infusion of RU28318 blocks aldosterone-salt hypertension","volume":"258","author":"Gomez-Sanchez","year":"1990","journal-title":"Am J Physiol"},{"key":"10.1053\/j.ajkd.2005.03.005_bib23","first-page":"3339","article-title":"The role of mineralocorticoid receptors in hypothalamic-pituitary-adrenal axis regulation in humans","volume":"83","author":"Young","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2005.03.005_bib24","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1159\/000054384","article-title":"Mineralocorticoid receptor also modulates basal activity of hypothalamus-pituitary-adrenocortical system in humans","volume":"68","author":"Deuschle","year":"1998","journal-title":"Neuroendocrinology"},{"key":"10.1053\/j.ajkd.2005.03.005_bib25","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.ASN.0000113320.57127.B9","article-title":"Sympathetic hyperactivity in chronic renal failure","volume":"15","author":"Koomans","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2005.03.005_bib26","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1056\/NEJM199904293401704","article-title":"Reduction of sympathetic hyperactivity by enalapril in patients with chronic renal failure","volume":"340","author":"Ligtenberg","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2005.03.005_bib27","article-title":"Blockade of brain mineralocorticoid receptors or Na+ channels prevents sympathetic hyperactivity and improves cardiac function in rats post-MI","author":"Huang","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1053\/j.ajkd.2005.03.005_bib28","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2005.03.005_bib29","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.ajkd.2005.03.005_bib30","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1046\/j.1523-1755.2000.00976.x","article-title":"Mineralocorticoid selectivity","volume":"57","author":"Farman","year":"2000","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2005.03.005_bib31","first-page":"288","article-title":"Response of plasma immunoreactive active renin, inactive renin, plasma renin activity, and aldosterone to hemodialysis in patients with diabetic nephropathy","volume":"33","author":"Sasamura","year":"1990","journal-title":"Clin Nephrol"},{"key":"10.1053\/j.ajkd.2005.03.005_bib32","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/clpt.1980.8","article-title":"Spironolactone and triamterene in volume-dependent essential hypertension","volume":"27","author":"DeCarvalho","year":"1980","journal-title":"Clin Pharmacol Ther"},{"key":"10.1053\/j.ajkd.2005.03.005_bib33","first-page":"41","article-title":"Low-dose spironolactone in the treatment of female hirsutism","volume":"32","author":"Ylostalo","year":"1987","journal-title":"Int J Fertil"},{"key":"10.1053\/j.ajkd.2005.03.005_bib34","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/ki.1988.194","article-title":"The role of aldosterone in potassium tolerance","volume":"34","author":"Sugarman","year":"1998","journal-title":"Kidney Int"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638605004324?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638605004324?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T01:31:26Z","timestamp":1759455086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638605004324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["S0272638605004324"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2005.03.005","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2005,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of Spironolactone on Blood Pressure and the Renin-Angiotensin-Aldosterone System in Oligo-Anuric Hemodialysis Patients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2005.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}